TerminatedPhase 4

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Stopped: Recommendation by DSMB, which felt that sufficient data had been obtained

United States134 participantsStarted 2015-05-21

Plain-language summary

This is a long-term follow-up to an earlier study, LA38-0411. Its purpose is to gather more information about the safety and efficacy of deferiprone in patients with sickle cell disease or other anemias who suffer from iron overload caused by regular blood transfusions.

Who can participate

Age range3 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Completed study LA38-0411
✓. Females of childbearing potential must have a negative pregnancy test result at Visit 1. In addition, if applicable, they must:
✓. Fertile heterosexual males and/or their partners must agree to use an effective method of contraception during the study and for 30 days following the last dose of study medication
✓. All patients and/or their authorized legal representatives must provide signed and dated written informed consent prior to the first study intervention, and assent will be obtained from patients who are considered to be minors. Patients must be able to adhere to study restrictions, appointments, and evaluation schedules.

Exclusion criteria

✕. Plan to participate in another clinical trial at any time from the day of enrollment until 30 days post-treatment in the current study
✕. For only those patients who were treated with deferoxamine in study LA38-0411 (Group 2): Presence of any medical condition (including clinically significant laboratory abnormalities, such as ALT (alanine aminotransferase) ≥ 5 x ULN or creatinine ≥ 2 x ULN), psychological condition, or psychiatric condition which in the opinion of the investigator would cause participation in the study to be unwise.
✕. Pregnant, breastfeeding, or planning to become pregnant during the study period.
✕. Treatment failure after 1 year on deferiprone which in the investigator's judgment indicates the need for the patient to be started on a different iron chelator

What they're measuring

Number of Patients With Adverse Events

Timeframe: From the first day of the study until the last study visit (Week 104 or early termination)

Trial details

NCT IDNCT02443545

SponsorApoPharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-04-30

Results submitted2021-05-13

View on ClinicalTrials.gov More Iron Overload trials